Myriad Genetics, Inc. is a prominent company focused on genetic diagnostics and personalized medicine, operating across the United States and in international markets. The firm develops and commercializes a diverse range of molecular diagnostic tests, with applications primarily in oncology, women's health, and mental health. In its oncology segment, Myriad offers several key products: the MyRisk Hereditary Cancer Test, a DNA sequencing analysis to identify risks for inherited cancers; the BRACAnalysis CDx Germline Companion Diagnostic Test, which uses DNA sequencing to inform treatment decisions for patients with metastatic breast, ovarian, pancreatic, or prostate cancers who have deleterious or suspected deleterious germline BRCA variants; and the MyChoice CDx Companion Diagnostic Test, a tumor-based assessment to determine homologous recombination deficiency status in ovarian cancer patients.